Cartesian Therapeutics faces a precarious financial outlook as it transitions to a pre-commercial mRNA-engineered cell therapy model, characterized by a 92.81% year-over-year revenue collapse in 2026Q1. The company's reliance on external capital to fund persis...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.46+152.4% vs -$0.88 | — vs $179,667 |
Q2 2026 Apr 30, 2026 | -$1.46-73.8% vs -$0.84 | $78,000-64.5% vs $219,800 |
Q2 2026 Mar 9, 2026 | -$1.38-68.3% vs -$0.82 | $947,000+529.9% vs $150,333 |
Q4 2025 Nov 6, 2025 | -$1.38-70.4% vs -$0.81 | $452,000+69.7% vs $266,333 |
FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company's common stock with effective grant dates of August 3, 2026 and August 6, 2026.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
Benchmark RNAC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cartesian Therapeutics, Inc. (RNAC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.87 | $231.23M | -1.57 | -92.81% | -4658.63% | — | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $26.38 | $3.3B | -202.92 | 91.34% | 6.15% | 15.05% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — |
Cartesian Therapeutics, Inc. (RNAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cartesian Therapeutics, Inc. (RNAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 17, 2026·SEC
Jun 9, 2026·SEC
Get notified when RNAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cartesian Therapeutics, Inc. (RNAC) stock FAQ — growth, dividends, profitability & financials explained
Cartesian Therapeutics, Inc. (RNAC) reported $1.5M in revenue for fiscal year 2025. This represents a 51% decrease from $3.0M in 2014.
Cartesian Therapeutics, Inc. (RNAC) saw revenue decline by 92.8% over the past year.
Cartesian Therapeutics, Inc. (RNAC) reported a net loss of $153.9M for fiscal year 2025.
Cartesian Therapeutics, Inc. (RNAC) had negative free cash flow of $78.2M in fiscal year 2025, likely due to heavy capital investments.
